{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Cycle 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"A patient was counted in a cycle if the patient received at least one dose of study drug during the cycle.","groups":[{"description":"Twice-weekly dosing with 2-hour IV infusions on days 1,4,8, and 11 of 3-week cycles","id":"OG000","title":"MRZ 0.5 mg/m^2"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Through study completion, an average of 6.09 weeks.","title":"Number of Patients Receiving Marizomib (MRZ) in Each Cycle","type":"SECONDARY","unitOfMeasure":"Participants"}